Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure

Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Nej Mo A 2208391, PDF, Blood Pressure

Zilebesiran lowers blood pressure in phase 1 trial

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Novel RNAi therapeutic lowers blood pressure in patients with hypertension - PACE-CME

Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure Impact - Cardiac Wire

Innovative Treatment for Hypertension: One Shot Every Quarter or Even Six Months • BioPharma Media

New Drug Could Control Blood Pressure With Just 2 Doses Per Year

Innovative Treatment for Hypertension: One Shot Every Quarter or Even Six Months • BioPharma Media

Roche's bet pays off as Alnylam hypertension med hits in phase 2

Notícias - Promising Results from Phase 2 Study Show Zilebesiran's Potential to Lower Blood Pressure for Up to 6 Months